Modulate Therapeutics, Inc. is a special purpose company created to develop one compound, IMM-01, to proof-of-concept. The project is fully financed by TVM Life Science Ventures VII. To date, IMM-01has completed pilot animal studies with the goal to begin GLP toxicology studies and file an Investigational New Drug (IND) application in 2016 and 2017 respectively.
If the IND is approved, IMM-01 will be tested in single ascending dose study in cancer patients and, if appropriate, in a multiple ascending dose study eventually leading to a clinical proof of concept (POC) in patients suffering from different cancer indications. Modulate Therapeutics, Inc. is funded by TVM Life Science Ventures VII and is led by an experienced management team.